Combination therapy of Thalidomide and Peginterferon in patients with progressive multiple myeloma

Ann Oncol. 2004 Jan;15(1):176-7. doi: 10.1093/annonc/mdh030.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Disease Progression
  • Female
  • Humans
  • Interferon alpha-2
  • Interferon-alpha* / administration & dosage
  • Interferon-alpha* / adverse effects
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / mortality
  • Multiple Myeloma / pathology
  • Polyethylene Glycols*
  • Recombinant Proteins
  • Survival Analysis
  • Thalidomide / administration & dosage
  • Thalidomide / adverse effects

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • Thalidomide
  • peginterferon alfa-2b
  • peginterferon alfa-2a